Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers

References

• Parker LA, Mechoulam R, Schlievert C. (2002). Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. NeuroReport, 13:567–70.
   PubMed Web of Science ®Google Scholar
• Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE, . (2004). Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn Schmiedebergs Arch Pharmacol, 369:294–9.
   PubMed Web of Science ®Google Scholar
• Holdcroft A, Maze M, Doré C, Tebbs S, Thompson S. (2006). A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology, 104:1040–6.
   PubMed Web of Science ®Google Scholar
• Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, . (2003). Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet, 362:1517–26.
   PubMed Web of Science ®Google Scholar
• Rog DJ, Nurmikko TJ, Friede T, Young CA. (2005). Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 65:812–9.
   PubMed Web of Science ®Google Scholar
• Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. (2006). Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, 45:50–2.
   PubMed Web of Science ®Google Scholar
• Agurell S, Carlsson S, Lindgren JE, Ohlsson A, Gillspie H, Hollister L. (1981). Interaction of THC with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography. Experientia, 37:1090–2.
   PubMedGoogle Scholar
• Ohisson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE. (1986). Single-dose kinetics of deutrium-labeled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom, 13:77–83.
   PubMedGoogle Scholar
• Samara E, Bialer M, Mechoulam R. (1988). Pharmacokinetics of cannabidiol in dogs. Drug Metab Dispos, 16:469–72.
   PubMed Web of Science ®Google Scholar
• Holdcroft A, Smith M, Smith B, Hodgson H, Evans FJ. (1997). Clinical trial experience with cannabinoids. Pharm Sci, 3:546–50.
   Google Scholar
• Welch SP, Eads M. (1999). Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res, 848:183–90.
   PubMed Web of Science ®Google Scholar
• Cichewicz DL, McCarthy EA. (2003). Antinociceptive synergy between Δ9-tetrahydrocannabinol and opioids after oral administration. JPET, 304:1010–5.
   PubMed Web of Science ®Google Scholar
• Touitou E, Fabin B, Dany S, Almog S. (1988). Transdermal delivery of tetrahydrocannabinol. Int J Pharm, 43:9–15.
   Web of Science ®Google Scholar
• Touitou E, Fabin B. (1988). Altered skin permeation of a highly lipophilic molecule: Tetrahydrocannabinol. Int J Pharm, 43:17–22.
   Web of Science ®Google Scholar
• Fabin B, Touitou E. (1991). Localization of lipophilic molecules penetrating rat skin in vivo by quantitative autoradiography. Int J Pharm, 74:59–65.
   Web of Science ®Google Scholar
• Challapalli PV, Stinchcomb AL. (2002). In vitro experiment optimization for measuring tetrahydrocannabinol skin permeation. Int J Pharm, 241:329–39.
   PubMed Web of Science ®Google Scholar
• Valiveti S, Hammell DC, Earles DC, Stinchcomb AL. (2004a). In vitro/in vivo correlation studies for transdermal delta 8-THC development. J Pharm Sci, 93:1154–64.
   PubMed Web of Science ®Google Scholar
• Valiveti S, Hammell DC, Earles DC, Stinchcomb AL. (2004b). Transdermal delivery of the synthetic cannabinoid WIN 55212-2: In vitro/in vivo correlation. Pharm Res, 21:1137–45.
   PubMed Web of Science ®Google Scholar
• Valiveti S, Kiptoo PK, Hammell DC, Stinchcomb AL. (2004). Transdermal permeation of WIN 55212-2 and CP 55940 in human skin in vitro. Int J Pharm, 278:173–80.
   PubMed Web of Science ®Google Scholar
• Stinchcomb AL, Valiveti S, Hammell DC, Ramsey DR. (2004). Human skin permeation of Delta8-tetrahydrocannabinol, cannabidiol and cannabinol. J Pharm Pharmacol, 56:291–7.
   PubMed Web of Science ®Google Scholar
• Lodzkia M, Godina B, Rakoua L, Mechoulamb R, Gallilyc R, Touitou E. (2003). Cannabidiol—transdermal delivery and anti-inflammatory effect in a murine model. J Control Release, 93:377–87.
   PubMed Web of Science ®Google Scholar
• StinchcombAL, NalluriBN. (2005). Transdermal delivery of cannabinoids. US patent no. 20050266061.
   Google Scholar
• Agu RU, Valiveti S, Paudel KS, Klausner M, Hayden PJ, Stinchcomb AL. (2006). Permeation of WIN 55212-2, a potent cannabinoid receptor agonist, across human tracheo-bronchial tissue in vitro and rat nasal epithelium in vivo. J Pharm Pharmacol, 58:1459–65.
   PubMed Web of Science ®Google Scholar
• Valiveti S, Agu RU, Hammell DC, Paudel KS, Earles DC, Wermeling DP, . (2007). Intranasal absorption of δ9-tetrahydrocannabinol and WIN 55212-2 mesylate in rats. Eur J Pharm Biopharm, 65:247–52.
   PubMed Web of Science ®Google Scholar
• Hussain AA, Dittert LW, Qaisi AM, Traboulsi A. (2002). Method for enhancement of delivery of THC by the administration of its prodrugs via the nasal route. US patent no. 6,380,175.
   Google Scholar
• Hussain AA, Dakkuri A, Itoh S. (2000). Nasal absorption of ondansetron in rats: An alternative route of drug delivery. Cancer Chemother Pharmacol, 45:432–4.
   PubMed Web of Science ®Google Scholar
• Bagger MA, Nielsen HW, Bechgaard E. (2001). Nasal bioavailability of peptide T in rabbits: Absorption enhancement by sodium glycocholate and glycofurol. Eur J Pharm Sci, 14:69–74.
   PubMed Web of Science ®Google Scholar
• Li L, Gorukanti S, Choi YM, Kim KH. (2000). Rapid-onset intranasal delivery of anticonvulsants: Pharmacokinetic and pharmacodynamic evaluation in rabbits. Int J Pharm, 199:65–76.
   PubMed Web of Science ®Google Scholar
• Hirai S, Yashiki T, Mima H. (1981). Mechanisms for the enhancement of the nasal absorption of insulin by surfactants. Int J Pharm, 9:173–84.
   Web of Science ®Google Scholar
• Huang Y, Donovan MD. (1998). Large molecule and particulate uptake in the nasal cavity: The effect of size on nasal absorption. Adv Drug Deliv Rev, 29:147–55.
   PubMed Web of Science ®Google Scholar
• Merkus FW, Verhoef JC, Marttin E, Romeijn SG, van der Kuy PH, Hermens WA, . (1999). Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev, 36:41–57.
   PubMed Web of Science ®Google Scholar
• Marttin E, Verhoef JC, Merkus FW. (1998). Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J Drug Target, 6:17–36.
   PubMed Web of Science ®Google Scholar
• Hjortkjár RK, Bechgaard E, Gizurarson SR, Suzdak C, Mcdonald P, Greenough RJ. (1999). Single- and repeated-dose local toxicity in the nasal cavity of rabbits after intranasal administration of different glycols for formulations containing benzodiazepines. J Pharm Pharmacol, 51:377–83.
   PubMed Web of Science ®Google Scholar
• Rahman M, Lau-Cam CA. (1999). Evaluation of the effect of polyethylene glycol 400 on the nasal absorption of nicardipine and verapamil in the rat. Pharmazie, 54:132–6.
   PubMed Web of Science ®Google Scholar
• Barthélémy P, Farah N, Laforet JP. (1995). Transcutol—product profile product information. Gattefossé, 1–10.
   Google Scholar
• Yazdanian M, Chen E. (1995). The effect of diethylene glycol monoethyl ether as a vehicle for topical delivery of ivermectin. Vet Res Comm, 19:309–19.
   PubMed Web of Science ®Google Scholar
• Mura P, Faucci MT, Bramanti G, Corti P. (2000). Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur J Pharm Sci, 9:365–72.
   PubMed Web of Science ®Google Scholar
• Cho YA, Gwak HS. (2004). Transdermal delivery of ketorolac tromethamine: Effects of vehicles and penetration enhancers. Drug Dev Ind Pharm, 30:557–64.
   PubMed Web of Science ®Google Scholar
• Ganem-Quintanar A, Lafforgue C, Falson-Rieg F, Buri P. (1997). Evaluation of the transepidermal permeation of diethyleneglycol monoethylether and skin water loss. Int J Pharm, 147:165–72.
   Web of Science ®Google Scholar
• Touitou E, Levi-Schaffer F, Dayan N, Alhaique F, Riccieri F. (1994). Modulation of caffeine skin delivery by carrier design: Liposomes versus permeation enhancers. Int J Pharm, 103:131–6.
   Web of Science ®Google Scholar
• Weiner B, ed. (1996). Physician’s desk reference generics. New Jersey: Medical Economics, 1083–6.
   Google Scholar
• Consroe P, Kennedy K, Schram K. (1991). Assay of plasma cannabidiol by capillary gas chromatography/ion trap mass spectroscopy following high-dose repeated daily oral administration in humans. Pharmacol Biochem Behav, 40:517–22. l
   PubMed Web of Science ®Google Scholar